{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T06:15:23Z","timestamp":1773814523903,"version":"3.50.1"},"reference-count":31,"publisher":"Japanese Society of Internal Medicine","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2022,5,1]]},"DOI":"10.2169\/internalmedicine.7635-21","type":"journal-article","created":{"date-parts":[[2021,10,11]],"date-time":"2021-10-11T22:11:49Z","timestamp":1633990309000},"page":"1415-1422","source":"Crossref","is-referenced-by-count":2,"title":["An Autopsy Confirmed Neuromyelitis Optica Spectrum Disorder with Extensive Brain White Matter Lesion and Optic Neuritis but Intact Spinal Cord, Clinically Mimicking a Secondary Progressive Multiple Sclerosis-like Course"],"prefix":"10.2169","volume":"61","author":[{"given":"Fumika","family":"Azuma","sequence":"first","affiliation":[{"name":"Department of Neurology, Fujita Health University Bantane Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuya","family":"Nokura","sequence":"additional","affiliation":[{"name":"Department of Neurology, Fujita Health University Bantane Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuharu","family":"Kako","sequence":"additional","affiliation":[{"name":"Department of Neurology, Fujita Health University Bantane Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mari","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Aichi Medical University, Institute for Medical Science of Aging, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinsui","family":"Tatsumi","sequence":"additional","affiliation":[{"name":"Department of Neurology, Yao Tokushukai General Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1212\/WNL.8.10.756","volume":"8","author":"S Okinaka","year":"1958","unstructured":"1. Okinaka S, Tsubaki T, Kuroiwa Y, Toyokura Y, Imamura Y. Multiple sclerosis and allied diseases in Japan; clinical characteristics. Neurology 8: 756-763, 1958.","journal-title":"Neurology","ISSN":"https:\/\/id.crossref.org\/issn\/0028-3878","issn-type":"print"},{"key":"2","doi-asserted-by":"publisher","unstructured":"2. Wingerchuk DM, Hogancamp WF, O'Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 53: 1107-1114, 1999.","DOI":"10.1212\/WNL.53.5.1107"},{"key":"3","doi-asserted-by":"publisher","unstructured":"3. Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet (London, England) 364: 2106-2112, 2004.","DOI":"10.1016\/S0140-6736(04)17551-X"},{"key":"4","doi-asserted-by":"publisher","unstructured":"4. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology 66: 1485-1489, 2006.","DOI":"10.1212\/01.wnl.0000216139.44259.74"},{"key":"5","doi-asserted-by":"publisher","unstructured":"5. Wingerchuk DM, Pittock SJ, Lucchinetti CF, Lennon VA, Weinshenker BG. A secondary progressive clinical course is uncommon in neuromyelitis optica. Neurology 68: 603-605, 2007.","DOI":"10.1212\/01.wnl.0000254502.87233.9a"},{"key":"6","doi-asserted-by":"publisher","unstructured":"6. Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 85: 177-189, 2015.","DOI":"10.1212\/WNL.0000000000001729"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Li Y, Xie P, Lv F, et al. Brain magnetic resonance imaging abnormalities in neuromyelitis optica. Acta Neurol Scand 118: 218-225, 2008.","DOI":"10.1111\/j.1600-0404.2008.01012.x"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Nagaishi A, Takagi M, Umemura A, et al. Clinical features of neuromyelitis optica in a large Japanese cohort: comparison between phenotypes. J Neurol Neurosurg Psychiatry 82: 1360-1364, 2011.","DOI":"10.1136\/jnnp-2011-300403"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Fujihara K, Nakashima I. Secondary progression and innate immunity in NMO: a possible link to alemtuzumab therapy? Neurol Neuroimmunol Neuroinflamm 1: e38, 2014.","DOI":"10.1212\/NXI.0000000000000038"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Gelfand JM, Cotter J, Klingman J, Huang EJ, Cree BA. Massive CNS monocytic infiltration at autopsy in an alemtuzumab-treated patient with NMO. Neurol Neuroimmunol Neuroinflamm 1: e34, 2014.","DOI":"10.1212\/NXI.0000000000000034"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Akaishi T, Takahashi T, Misu T, et al. Progressive patterns of neurological disability in multiple sclerosis and neuromyelitis optica spectrum disorders. Sci Rep 10: 13890, 2020.","DOI":"10.1038\/s41598-020-70919-w"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 17: 162-173, 2018.","DOI":"10.1016\/S1474-4422(17)30470-2"},{"key":"13","doi-asserted-by":"publisher","unstructured":"13. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 46: 907-911, 1996.","DOI":"10.1212\/WNL.46.4.907"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Lublin FD, Coetzee T, Cohen JA, Marrie RA, Thompson AJ. The 2013 clinical course descriptors for multiple sclerosis: a clarification. Neurology 94: 1088-1092, 2020.","DOI":"10.1212\/WNL.0000000000009636"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Miller DH, Weinshenker BG, Filippi M, et al. Differential diagnosis of suspected multiple sclerosis: a consensus approach. Mult Scler 14: 1157-1174, 2008.","DOI":"10.1177\/1352458508096878"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Geraldes R, Ciccarelli O, Barkhof F, et al. The current role of MRI in differentiating multiple sclerosis from its imaging mimics. Nat Rev Neurol 14: 199-213, 2018.","DOI":"10.1038\/nrneurol.2018.14"},{"key":"17","unstructured":"17. Tanaka K. [MS (multiple sclerosis) and NMO (neuromyelitis optica)] clinical symptoms, MRI and laboratory findings of NMO: significance of anti-aquaporin-4 antibody. Brain Med 22: 331-336, 2010 (in Japanese)."},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Kitley J, Leite MI, Nakashima I, et al. Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan. Brain J Neurol 135: 1834-1849, 2012.","DOI":"10.1093\/brain\/aws109"},{"key":"19","unstructured":"19. Yoshida M. Neuropathology of demyelinating diseases in Japan. J Neurol Disord Stroke 2: 1086, 2014."},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Pittock SJ, Lennon VA, Krecke K, Wingerchuk DM, Lucchinetti CF, Weinshenker BG. Brain abnormalities in neuromyelitis optica. Arch Neurol 63: 390-396, 2006.","DOI":"10.1001\/archneur.63.3.390"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Pittock SJ, Weinshenker BG, Lucchinetti CF, Wingerchuk DM, Corboy JR, Lennon VA. Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Arch Neurol 63: 964-968, 2006.","DOI":"10.1001\/archneur.63.7.964"},{"key":"22","unstructured":"22. Nakashima I, Fujihara K, Miyazawa I, Watanabe S, Itoyama Y. Clinical and radiological features of multiplesclerosis patients positive for NMO-lgG. Shinkeinaika 65: 377-381, 2006 (in Japanese)."},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Furukawa T, Matsui N, Tanaka K, Izumi Y, Kaji R. A case of neuromyelitis optica spectrum disorder (NMOSD) with Sj\u00f6gren's syndrome manifested only brain involvement by preceding parotitis. Rinsho Shinkeigaku Clin Neurol 57: 77-81, 2017 (in Japanese).","DOI":"10.5692\/clinicalneurol.cn-000924"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Carvalho DC, Tironi TS, Freitas DS, Kleinpaul R, Talim NC, Lana-Peixoto MA. Sj\u00f6gren syndrome and neuromyelitis optica spectrum disorder co-exist in a common autoimmune milieu. Arq Neuropsiquiatr 72: 619-624, 2014.","DOI":"10.1590\/0004-282X20140097"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Qiao L, Wang Q, Fei Y, et al. The clinical characteristics of primary Sj\u00f6gren's syndrome with neuromyelitis optica spectrum disorder in China: a STROBE-compliant article. Medicine 94: e1145, 2015.","DOI":"10.1097\/MD.0000000000001145"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Wang KC, Lin KH, Lee TC, et al. Poor responses to interferon-beta treatment in patients with neuromyelitis optica and multiple sclerosis with long spinal cord lesions. PloS One 9: e98192, 2014.","DOI":"10.1371\/journal.pone.0098192"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Misu T, Fujihara K, Kakita A, et al. Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis. Brain J Neurol 130: 1224-1234, 2007.","DOI":"10.1093\/brain\/awm047"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol 6: 805-815, 2007.","DOI":"10.1016\/S1474-4422(07)70216-8"},{"key":"29","doi-asserted-by":"publisher","unstructured":"29. Yanagawa K, Kawachi I, Toyoshima Y, et al. Pathologic and immunologic profiles of a limited form of neuromyelitis optica with myelitis. Neurology 73: 1628-1637, 2009.","DOI":"10.1212\/WNL.0b013e3181c1deb9"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Paz Sold\u00e1n MM, Novotna M, Abou Zeid N, et al. Relapses and disability accumulation in progressive multiple sclerosis. Neurology 84: 81-88, 2015.","DOI":"10.1212\/WNL.0000000000001094"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Vaughn CB, Jakimovski D, Kavak KS, et al. Epidemiology and treatment of multiple sclerosis in elderly populations. Nat Rev Neurol 15: 329-342, 2019.","DOI":"10.1038\/s41582-019-0183-3"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/61\/9\/61_7635-21\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,7]],"date-time":"2022-05-07T03:32:39Z","timestamp":1651894359000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/61\/9\/61_7635-21\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,1]]},"references-count":31,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.7635-21","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,1]]},"article-number":"7635-21"}}